Clinical Trials

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

Parexel's new biotech incubator isn't just another funding vehicle. It's a strategic move to embed regulatory expertise at the seed stage, betting that early guidance is more valuable than capital alone.

SeaStar Medical prepares to present its life-saving organ failure technology to investors. We explore its newly approved product, pivotal adult trial, and vast market potential.

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

A new enzyme blend for dogs boasts a 92% success rate in a clinical trial. We analyze the data and what it means for the pet supplement industry's future.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

Companies like eGenesis are turning science fiction into reality with gene-edited pig organs. This is the story of a medical revolution at a crossroads.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.